Showing results (181-190 of 239) with videos related to

Sort By:
Pageof 24
Breast (Edinburgh, Scotland)|September 20, 2024
Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelinesDavid Groheux, Sofia C Vaz, Philip Poortmans, et al.
The New England Journal of Medicine|February 27, 2020
Pembrolizumab for Early Triple-Negative Breast CancerPeter Schmid, Javier Cortes, Lajos Pusztai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation seriesChristine Desmedt, Fanny Piette, Sherene Loi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2026
Transcriptomic insights into lobular breast cancer biology and patient outcomes: analysis of the MINDACT clinical trialChristine Desmedt, Ha-Linh Nguyen, François Richard, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2010
Breast cancer in pregnancy: recommendations of an international consensus meetingFrédéric Amant, Sarah Deckers, Kristel Van Calsteren, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 14, 2017
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer ProgramShusma C Doebar, Leen Slaets, Fatima Cardoso, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 13, 2024
Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)Sofia C Vaz, John Patrick Pilkington Woll, Fatima Cardoso, et al.
Breast Cancer Research : BCR|November 28, 2024
Metastatic recurrence in women diagnosed with non-metastatic breast cancer: a systematic review and meta-analysisEileen Morgan, Colette O'Neill, Richa Shah, et al.
Molecular Cancer Therapeutics|October 16, 2004
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxelVirginie Durbecq, Marianne Paesmans, Fatima Cardoso, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2022
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trialRichard D Gelber, Xin V Wang, Bernard F Cole, et al.
Pageof 24